Início › Carcinoma de Células Escamosas de Cabeça e Pescoço › Texas

Ensaios clínicos de Carcinoma de Células Escamosas de Cabeça e Pescoço em Texas

69 estudos para Carcinoma de Células Escamosas de Cabeça e Pescoço estão buscando participantes em locais em Texas.

Cidades em Texas

Texto oficial do estudo (Inglês)

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Site#0102, Houston
Site #0152, Waco

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06788990

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University of Texas MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics (START), San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06465069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #46, Austin
Exelixis Clinical Site #89, Dallas
Exelixis Clinical Site #73, Irving
e mais 2

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07189871

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center - Conroe, Conroe
University of Texas MD Anderson Cancer Center, Houston
The University of Texas, MD Anderson Cancer Center - West Houston, Houston
e mais 3

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07090499

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 5, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07085091

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

NEXT Houston, Galveston
NEXT Oncology - PARENT, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07360314

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Houston
Research Site, Round Rock

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

UT Southwestern Medical Center, Dallas
Texas Oncology - San Antonio, Fredericksburg
MD Anderson Cancer Center, Houston
e mais 2

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07276399

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Baylor, Scott and White Research Institute, Dallas

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06047379

Intratumoral N17350 in Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07339176

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Oncology Consultants, P.A., Houston
University of Texas M.D. Anderson Cancer Center, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Texas Oncology (Balcones) - SCRI, Austin
MD Anderson Cancer Center, Houston
START South Texas Accelerated Research Therapeutics, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT05267626

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

MD Anderson Cancer Center, Houston
START Center for Cancer Research, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07109726

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

UT Southwestern Medical Center, Dallas
DHR Health Advance Care Center, Edinburg
The Center for Cancer and Blood Disorders, Forth Worth
e mais 1

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NEXT Oncology Austin, Austin
NEXT Oncology - Dallas, Irving
NEXT Oncology - San Antonio, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT06657222

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

MD Anderson Cancer Center, Houston
Site 102 - START San Antonio, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT07462377

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

MD Anderson Cancer Center, Houston
START San Antonio, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06597721

A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

Site US074, Tyler

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07807163

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

START Dallas Forth Worth, Fort Worth

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT07602842

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

M. D. Anderson Cancer Center, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07216105

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

START-San Antonio, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT06084481

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Joe Arrington Cancer Research & Treatment Center, Lubbock
Renovatio Clinical, The Woodlands

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06769698

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Research Site, Houston
Research Site, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07115043

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Next Oncology Dallas /ID# 276659, Irving

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07241039

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Normunity Investigational Site, Dallas
Normunity Investigational Site, Houston
Normunity Investigational Site, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07182149

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Houston Methodist Hospital, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT04895709

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

MD Anderson in The Woodlands, Conroe
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Michael E DeBakey VA Medical Center, Houston
e mais 4

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT04333537

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

START San Antonio, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 13 de ago. de 2026 · NCT05985655

SMP-3124LP in Adults With Advanced Solid Tumors

MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT06526819

A Study of MGC026 in Participants With Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston
University of Texas Health Science Center at Houston, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT06242470

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

M D Anderson Cancer Center, Houston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT05674396

A Study of DM005 in Patients With Advanced Solid Tumors

Sarah Cannon Research Institute at Mary Crowley, Dallas

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06515990

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Texas Oncology - West Texas, Amarillo
Texas Oncology, P.A., Dallas
Texas Oncology Gulf Coast, Pearland

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06330064

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Texas Oncology, Dallas
Oncology Consultants, Houston
Texas Oncology, Tyler

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de jul. de 2026 · NCT03526835

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

The University of Texas Health Science Center at Tyler, Tyler

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de jul. de 2026 · NCT04198766

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
UT Southwestern Medical Center - Redbird, Dallas
Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
e mais 8

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT05208762

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
University of Texas Southwestern, Dallas
University of Texas MD Anderson Cancer Center, Houston
e mais 1

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 7 de jul. de 2026 · NCT05768139

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Oncology Consultants, PA, Houston
Oncology Consultants, PA., Houston
The University of Texas M.D. Anderson Cancer Center, Houston
e mais 5

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT04389632

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston
START, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 23 de jun. de 2026 · NCT06993844

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.